drugset / Trial / NCT04387201
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Phase 4
Completed
23 enrolled
The University of Texas Health Science Center, Houston
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedCrossoverOpen-labelBasic science
Summary
This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborate with GLP-1 analogs to induce the formation of brown fat, which has anti-diabetic properties. The results will guide future obesity and diabetes mellitus therapies.
Timeline
- Start
- 2020-05-15
- Primary completion
- 2023-10-06
- Completion
- 2023-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Background | Vitamin B12 | Other / unclassified | 1000 ug | Subcutaneous |